Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCHOR: Vascepa in High Triglycerides on Statins
NCT01047501Phase 3Completed
- Sponsor
- Amarin Corporation plc
- Start
- Dec 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omega-3 long-chain polyunsaturated fatty acids in hypertriglyceridemia (3 arms), sponsored by Amarin Corporation plc. Primary endpoint: Difference Between AMR101 and Placebo in Triglyceride Lowering Effect at 12 weeks. Started Dec 2009; status: completed.
02
Drugs
omega-3 long-chain polyunsaturated fatty acids
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT01047501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01047501.